-
1
-
-
84892649479
-
Standards of medical care in diabetes–2014
-
American Diabetes Association. Standards of medical care in diabetes–2014. Diabetes Care. 2014;37 Suppl 1:S14–80.
-
(2014)
Diabetes Care
, vol.37
, pp. S14-S80
-
-
-
2
-
-
84860144206
-
American Association of Clinical Endocrinologists’ guidelines for management of dyslipidemia and prevention of atherosclerosis
-
Jellinger PS, Smith DA, Mehta AE, Ganda O, Handelsman Y, Rodbard HW, et al. American Association of Clinical Endocrinologists’ guidelines for management of dyslipidemia and prevention of atherosclerosis. Endocr Pract. 2012;18(Suppl 1):1–78.
-
(2012)
Endocr Pract
, vol.18
-
-
Jellinger, P.S.1
Smith, D.A.2
Mehta, A.E.3
Ganda, O.4
Handelsman, Y.5
Rodbard, H.W.6
-
3
-
-
84859049036
-
The association of hypertriglyceridemia with cardiovascular events and pancreatitis: a systematic review and meta-analysis
-
PID: 22463676
-
Murad MH, Hazem A, Coto-Yglesias F, Dzyubak S, Gupta S, Bancos I, et al. The association of hypertriglyceridemia with cardiovascular events and pancreatitis: a systematic review and meta-analysis. BMC Endocr Disord. 2012;12:2.
-
(2012)
BMC Endocr Disord
, vol.12
, pp. 2
-
-
Murad, M.H.1
Hazem, A.2
Coto-Yglesias, F.3
Dzyubak, S.4
Gupta, S.5
Bancos, I.6
-
4
-
-
84924334268
-
Plasma triglycerides predict ten-years all-cause mortality in outpatients with type 2 diabetes mellitus: a longitudinal observational study
-
PID: 25301574
-
Miselli MA, Nora ED, Passaro A, Tomasi F, Zuliani G. Plasma triglycerides predict ten-years all-cause mortality in outpatients with type 2 diabetes mellitus: a longitudinal observational study. Cardiovasc Diabetol. 2014;13:135.
-
(2014)
Cardiovasc Diabetol
, vol.13
, pp. 135
-
-
Miselli, M.A.1
Nora, E.D.2
Passaro, A.3
Tomasi, F.4
Zuliani, G.5
-
5
-
-
85027956925
-
Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association
-
PID: 21502576
-
Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123:2292–333.
-
(2011)
Circulation
, vol.123
, pp. 2292-2333
-
-
Miller, M.1
Stone, N.J.2
Ballantyne, C.3
Bittner, V.4
Criqui, M.H.5
Ginsberg, H.N.6
-
6
-
-
84892772956
-
Residual macrovascular risk in 2013: what have we learned?
-
PID: 24460800
-
Fruchart JC, Davignon J, Hermans MP, Al-Rubeaan K, Amarenco P, Assmann G, et al. Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol. 2014;13:26.
-
(2014)
Cardiovasc Diabetol
, vol.13
, pp. 26
-
-
Fruchart, J.C.1
Davignon, J.2
Hermans, M.P.3
Al-Rubeaan, K.4
Amarenco, P.5
Assmann, G.6
-
7
-
-
80051670126
-
Fish oils in the treatment of dyslipidemia and cardiovascular disease
-
Kwiterovich PO, (ed), Lippincott Williams & Wolters Kluwer, Philadelphia
-
Bays H. Fish oils in the treatment of dyslipidemia and cardiovascular disease. In: Kwiterovich PO, editor. The Johns Hopkins textbook of dyslipidemia. Philadelphia: Lippincott Williams & Wolters Kluwer; 2010. p. 245–57.
-
(2010)
The Johns Hopkins textbook of dyslipidemia
, pp. 245-257
-
-
Bays, H.1
-
8
-
-
79961054708
-
Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events
-
COI: 1:CAS:528:DC%2BC3MXhs1eju7zE, PID: 22051327
-
Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol. 2011;58:2047–67.
-
(2011)
J Am Coll Cardiol
, vol.58
, pp. 2047-2067
-
-
Mozaffarian, D.1
Wu, J.H.2
-
9
-
-
85118092730
-
-
Lovaza [package insert]. Research Triangle Park: GlaxoSmithKline; 2014
-
Lovaza [package insert]. Research Triangle Park: GlaxoSmithKline; 2014.
-
-
-
-
10
-
-
85118090691
-
-
Vascepa [package insert]. Bedminster: Amarin Pharma Inc.; 2013
-
Vascepa [package insert]. Bedminster: Amarin Pharma Inc.; 2013.
-
-
-
-
11
-
-
81155139591
-
Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis
-
COI: 1:CAS:528:DC%2BC3MXhsVaht7vN, PID: 21975919
-
Wei MY, Jacobson TA. Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis. Curr Atheroscler Rep. 2011;13:474–83.
-
(2011)
Curr Atheroscler Rep
, vol.13
, pp. 474-483
-
-
Wei, M.Y.1
Jacobson, T.A.2
-
12
-
-
0031425356
-
Safety and efficacy of Omacor in severe hypertriglyceridemia
-
COI: 1:STN:280:DyaK1M%2FotFaluw%3D%3D, PID: 9865671
-
Harris WS, Ginsberg HN, Arunakul N, Shachter NS, Windsor SL, Adams M, et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk. 1997;4:385–91.
-
(1997)
J Cardiovasc Risk
, vol.4
, pp. 385-391
-
-
Harris, W.S.1
Ginsberg, H.N.2
Arunakul, N.3
Shachter, N.S.4
Windsor, S.L.5
Adams, M.6
-
13
-
-
80051784104
-
Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels [from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension (MARINE) trial]
-
COI: 1:CAS:528:DC%2BC3MXhtVajtrbF, PID: 21683321
-
Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels [from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension (MARINE) trial]. Am J Cardiol. 2011;108:682–90.
-
(2011)
Am J Cardiol
, vol.108
, pp. 682-690
-
-
Bays, H.E.1
Ballantyne, C.M.2
Kastelein, J.J.3
Isaacsohn, J.L.4
Braeckman, R.A.5
Soni, P.N.6
-
14
-
-
84866124338
-
Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study)
-
COI: 1:CAS:528:DC%2BC38XhtVyktL7E, PID: 22819432
-
Ballantyne CM, Bays HE, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol. 2012;110:984–92.
-
(2012)
Am J Cardiol
, vol.110
, pp. 984-992
-
-
Ballantyne, C.M.1
Bays, H.E.2
Kastelein, J.J.3
Stein, E.4
Isaacsohn, J.L.5
Braeckman, R.A.6
-
15
-
-
0037126526
-
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report
-
Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–421.
-
(2002)
Circulation
, vol.106
, pp. 3143-3421
-
-
-
16
-
-
84908397421
-
National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1—executive summary
-
PID: 25234560
-
Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1—executive summary. J Clin Lipidol. 2014;8:473–88.
-
(2014)
J Clin Lipidol
, vol.8
, pp. 473-488
-
-
Jacobson, T.A.1
Ito, M.K.2
Maki, K.C.3
Orringer, C.E.4
Bays, H.E.5
Jones, P.H.6
-
17
-
-
84893560587
-
Potential benefits of icosapent ethyl on the lipid profile: case studies
-
COI: 1:CAS:528:DC%2BC2cXhtlWhu7bM, PID: 24516343
-
Hilleman DE, Malesker MA. Potential benefits of icosapent ethyl on the lipid profile: case studies. Clin Med Insights Cardiol. 2014;8:13–5.
-
(2014)
Clin Med Insights Cardiol
, vol.8
, pp. 13-15
-
-
Hilleman, D.E.1
Malesker, M.A.2
-
18
-
-
84906924767
-
A retrospective case series of the lipid effects of switching from omega-3 fatty acid ethyl esters to icosapent ethyl in hyperlipidemic patients
-
PID: 24977343
-
Castaldo RS. A retrospective case series of the lipid effects of switching from omega-3 fatty acid ethyl esters to icosapent ethyl in hyperlipidemic patients. Postgrad Med. 2014;126:268–73.
-
(2014)
Postgrad Med
, vol.126
, pp. 268-273
-
-
Castaldo, R.S.1
-
19
-
-
84866146620
-
Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline
-
COI: 1:CAS:528:DC%2BC38XhtlymurbF, PID: 22962670
-
Berglund L, Brunzell JD, Goldberg AC, Goldberg IJ, Sacks F, Murad MH, et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97:2969–89.
-
(2012)
J Clin Endocrinol Metab
, vol.97
, pp. 2969-2989
-
-
Berglund, L.1
Brunzell, J.D.2
Goldberg, A.C.3
Goldberg, I.J.4
Sacks, F.5
Murad, M.H.6
-
20
-
-
0015348189
-
Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
-
COI: 1:CAS:528:DyaE38Xkslagsbw%3D, PID: 4337382
-
Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.
-
(1972)
Clin Chem
, vol.18
, pp. 499-502
-
-
Friedewald, W.T.1
Levy, R.I.2
Fredrickson, D.S.3
-
21
-
-
84880019277
-
Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200–500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study
-
COI: 1:CAS:528:DC%2BC3sXht1ejtb%2FN, PID: 23835245
-
Brinton EA, Ballantyne CM, Bays HE, Kastelein JJ, Braeckman RA, Soni PN. Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200–500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study. Cardiovasc Diabetol. 2013;12:100.
-
(2013)
Cardiovasc Diabetol
, vol.12
, pp. 100
-
-
Brinton, E.A.1
Ballantyne, C.M.2
Bays, H.E.3
Kastelein, J.J.4
Braeckman, R.A.5
Soni, P.N.6
-
22
-
-
33749154105
-
Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review
-
COI: 1:CAS:528:DC%2BD28XhtVajsr3L, PID: 16530201
-
Balk EM, Lichtenstein AH, Chung M, Kupelnick B, Chew P, Lau J. Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis. 2006;189:19–30.
-
(2006)
Atherosclerosis
, vol.189
, pp. 19-30
-
-
Balk, E.M.1
Lichtenstein, A.H.2
Chung, M.3
Kupelnick, B.4
Chew, P.5
Lau, J.6
-
23
-
-
0345109256
-
Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico
-
GISSI Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet. 1999;354:447–55.
-
(1999)
Lancet
, vol.354
, pp. 447-455
-
-
-
24
-
-
53049110571
-
Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial
-
GISSI-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1223–30.
-
(2008)
Lancet
, vol.372
, pp. 1223-1230
-
-
Investigators, G.I.S.S.I.-H.F.1
-
25
-
-
78549233384
-
n-3 fatty acids and cardiovascular events after myocardial infarction
-
COI: 1:CAS:528:DC%2BC3cXhsVykt7jI, PID: 20929341
-
Kromhout D, Giltay EJ, Geleijnse JM. n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med. 2010;363:2015–26.
-
(2010)
N Engl J Med
, vol.363
, pp. 2015-2026
-
-
Kromhout, D.1
Giltay, E.J.2
Geleijnse, J.M.3
-
26
-
-
84864219466
-
n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia
-
ORIGIN Trial Investigators. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367:309–18.
-
(2012)
N Engl J Med
, vol.367
, pp. 309-318
-
-
-
27
-
-
78650169331
-
OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction
-
COI: 1:CAS:528:DC%2BC3cXhsV2gu73K, PID: 21060071
-
Rauch B, Schiele R, Schneider S, Diller F, Victor N, Gohlke H, et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation. 2010;122:2152–9.
-
(2010)
Circulation
, vol.122
, pp. 2152-2159
-
-
Rauch, B.1
Schiele, R.2
Schneider, S.3
Diller, F.4
Victor, N.5
Gohlke, H.6
-
28
-
-
33947583493
-
Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis
-
COI: 1:CAS:528:DC%2BD2sXjs1Ohtro%3D, PID: 17398308
-
Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369:1090–8.
-
(2007)
Lancet
, vol.369
, pp. 1090-1098
-
-
Yokoyama, M.1
Origasa, H.2
Matsuzaki, M.3
Matsuzawa, Y.4
Saito, Y.5
Ishikawa, Y.6
-
29
-
-
49749128376
-
Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS)
-
COI: 1:CAS:528:DC%2BD1cXhtVensb7J, PID: 18667204
-
Saito Y, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Ishikawa Y, et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis. 2008;200:135–40.
-
(2008)
Atherosclerosis
, vol.200
, pp. 135-140
-
-
Saito, Y.1
Yokoyama, M.2
Origasa, H.3
Matsuzaki, M.4
Matsuzawa, Y.5
Ishikawa, Y.6
-
30
-
-
84869170925
-
Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial
-
COI: 1:CAS:528:DC%2BC38XhvVCmtrjM, PID: 23128104
-
Mozaffarian D, Marchioli R, Macchia A, Silletta MG, Ferrazzi P, Gardner TJ, et al. Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial. JAMA. 2012;308:2001–11.
-
(2012)
JAMA
, vol.308
, pp. 2001-2011
-
-
Mozaffarian, D.1
Marchioli, R.2
Macchia, A.3
Silletta, M.G.4
Ferrazzi, P.5
Gardner, T.J.6
-
31
-
-
84875802805
-
Long-chain omega-3 polyunsaturated fatty acids and risk of stroke: a meta-analysis
-
COI: 1:CAS:528:DC%2BC3sXmtVClsQ%3D%3D, PID: 23179632
-
Larsson SC, Orsini N, Wolk A. Long-chain omega-3 polyunsaturated fatty acids and risk of stroke: a meta-analysis. Eur J Epidemiol. 2012;27:895–901.
-
(2012)
Eur J Epidemiol
, vol.27
, pp. 895-901
-
-
Larsson, S.C.1
Orsini, N.2
Wolk, A.3
-
32
-
-
84877624255
-
-
The Risk and Prevention Study Collaborative Group. n-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med. 2013;368:1800–8.
-
(2013)
N Engl J Med
, vol.368
, pp. 1800-1808
-
-
-
33
-
-
68149166448
-
Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease
-
COI: 1:CAS:528:DC%2BD1MXptVejsLw%3D, PID: 19423946
-
Matsuzaki M, Yokoyama M, Saito Y, Origasa H, Ishikawa Y, Oikawa S, et al. Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease. Circ J. 2009;73:1283–90.
-
(2009)
Circ J
, vol.73
, pp. 1283-1290
-
-
Matsuzaki, M.1
Yokoyama, M.2
Saito, Y.3
Origasa, H.4
Ishikawa, Y.5
Oikawa, S.6
-
34
-
-
84903727023
-
Loss-of-function mutations in APOC3, triglycerides, and coronary disease
-
TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014;371:22–31.
-
(2014)
N Engl J Med
, vol.371
, pp. 22-31
-
-
-
36
-
-
85118091377
-
-
A study of AMR101 to evaluate its ability to reduce cardiovascular events in high risk patients with hypertriglyceridemia and on statin (REDUCE-IT). Accessed Nov 26, 2014
-
A study of AMR101 to evaluate its ability to reduce cardiovascular events in high risk patients with hypertriglyceridemia and on statin (REDUCE-IT). http://clinicaltrials.gov/show/NCT01492361. Accessed Nov 26, 2014.
-
-
-
|